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Inﬂammatory myoﬁbroblastic tumor is a rare but benign clinical entity. Its ability to mimic malignancy
poses a diagnostic challenge. Here, we report the ﬁrst case in Australia, of inﬂammatory myoﬁbroblastic
tumor in the bladder in a 40-year-old male, removed via transurethral resection.
Crown Copyright  2016 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Inﬂammatory myoﬁbroblastic tumor (IMT) often presents a
diagnostic challenge due to its obscure pathogenesis and ability to
mimic malignancy. The ﬁrst case series reported, involving lung,
was described by Brunn in 1939.1 Since then, involvement of other
organs, including genitourinary tract, have been reported.2 Here,
we report a case of IMT in the bladder in a 40-year-old male,
removed via transurethral resection. To the best of our knowledge,
this is the ﬁrst case of IMT of the bladder reported in Australia.Case presentation
A 40-year-oldmalewas referred to urology clinic with hematuria,
dysuria, and abdominal pain localized to the suprapubic region.
Initial investigation of renal tract ultrasound showed a 4.1 cm right-
sided bladder wall mass. His medical history included hypertension,
type 2 diabetes mellitus, and hypercholesterolemia. He was an ex-
smoker, had a BMI of 32, and had worked in the paint industry for
10 years. He had no prior surgical history or history of malignancy.
On examination, tenderness was elicited in the suprapubic re-
gion, but no masses were detected. Bladder scan demonstrated
80 mL residual volume. His renal function was normal, withon Road, Clayton, VIC 3168,
Tanny).
vier Inc. This is an open access articreatinine 50 mmol/L, and estimated glomerular ﬁltration rate
>90 mL/min. Urine microscopy demonstrated microscopic hema-
turia. Urine culture showed no signiﬁcant growth.
He was referred for computed tomography urography (CTU)
scan, which revealed a large right-sided bladder malignancy, pro-
truding into the bladder lumen (Fig. 1). No upper tract masses were
identiﬁed.
He subsequently underwent cystoscopy and transurethral
resection of bladder tumor (TURBT). Intra-operative ﬁndings
showed a large solid bladder mass, measuring approximately 5 cm,
involving the right lateral wall. This was clear of the ureteric ori-
ﬁces. Its smooth surface was not typical of urothelial carcinomas.
On bimanual examination, there was no evidence of extra-vesical
extension. Subsequent staging computed tomography chest scan
showed no intrathoracic metastatic disease.
Histopathology result demonstrated features consistent with
IMT. Bladder tissue, including muscle, was widely inﬁltrated by
lesion comprising cellular fascicles of spindle cells in mixed
edematous, myxoid and ﬁbrous stroma. The cells showed moderate
nuclear atypia in areas, with nuclear size variation, and scattered
cells had single prominent nucleoli. Mitotic activity was incon-
spicuous (<1 mf/10 hpf), with no atypical mitotic ﬁgures identiﬁed.
Throughout the lesion, there were foci of necrosis and hemorrhage.
The surface urothelium showed areas of cystitis cystica/glandularis,
but no papillary neoplasm was seen, and no urothelial carcinoma-
in-situ was identiﬁed. Immunohistochemical staining was posi-
tive for cytokeratin AE1/3, vimentin (Fig. 2), actin, ALK (Fig. 3), and
desmin.cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
Figure 1. CTU showing a large right-sided bladder malignancy, protruding into the
bladder lumen. Arrow added to identify the referenced bladder malignancy protruding
into bladder lumen.
Figure 3. Histopathology image showing spindle cells with ALK-positive staining.
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decision made for close follow-up with imaging. At the time of
article submission, our patient had been referred for repeat CTU and
urology follow-up review at 6 months post-operation.Discussion
IMT of the urinary bladder was ﬁrst reported by Roth in 1980.2 It
has been associated with trauma, surgery and infection, but ma-
jority occur spontaneously. It is more common in children and
young adults, but can occur at any age. Histologically, IMT is char-
acterized by proliferation of atypical spindle cells and inﬁltration of
inﬂammatory cells. Histologically, IMT can mimic sarcomatoid
carcinoma, leiomyosarcoma, or rhabdomyosarcoma, making diag-
nosis difﬁcult.3
ALK, a protein over expressed in anasplatic large-cell lymphoma,
is over expressed in IMTs,3 and is a useful marker to differentiate
IMTs from other malignant spindle-cell tumors. In our case, indeed
tumor tissue was ALK-positive.
A systematic review by Teoh et al evaluated IMT cases from
January 1900 to June 2013, which included 182 patients with mean
age 38.9 16.6 years.4 The commonest presentationwas hematuriaFigure 2. Histopathology image showing spindle cells with vimentin-positive staining.(71.9%) and dysuria (19.8%). Most patients underwent TURBT
(60.8%); others had partial (29.2%) and radical cystectomy (9.2%). Of
the 182 patients, 5 had local recurrence. Two of these occurred
within 6 months, requiring repeat TURBT. While partial or radical
cystectomy ensures complete resection of IMT, TURBT is also suit-
able given the benign course of IMT. Regular follow-up is required,
including cystoscopy and CTU, for monitoring of recurrence, and
distance metastases.
Despite tending to a benign course, 4% of tumors may recur
following excision.4 Thus far,1 case of metastases has been reported
in the literature, involving a 71-year-old male with IMT of the
bladder, who developed metastases to multiple lymph nodes, bone,
and soft tissue.5Conclusion
In conclusion, IMT is a rare but benign clinical entity. It is often
adequately managed with TURBT, followed by interval clinical and
radiological monitoring for local recurrence and distant metastases.
To the best of our knowledge, our case of IMT of the bladder is the
ﬁrst reported case in Australia, contributing to the literature of
global case series and reports.Disclosure of sources of ﬁnancial support
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